-
恶性肿瘤的发生、发展和转归非常复杂, 同一肿瘤在不同阶段的生物学表现差异明显, 肿瘤的治疗方案亦具多样性。目前, 肿瘤的治疗方式主要包括手术、化疗、放疗3种治疗方案, 部分肿瘤亦可选择内分泌治疗、光动力疗法等。无论哪种治疗方案, 若能早期及时对其疗效进行监测, 有利于临床医师对治疗方案的选择和实施个体化治疗。传统解剖学成像如B超、CT、MRI等对肿瘤疗效的监测多在治疗后数周甚至数月之后[1], 不利于临床医师对于疗效不佳的患者快速制定治疗方案, 因此并非理想的早期监测手段。PET-CT通过代谢功能成像的特点克服了传统解剖成像的缺陷。目前, 18F-FDG作为临床上最常用的葡萄糖类代谢显像剂和最常用的细胞增殖显像剂3′-脱氧-3′-18F-氟代胸腺嘧啶(3′-deoxy-3′-18F-fluorothymidine, 18F-FLT)在肿瘤的诊断、分期及疗效评价中已有较深入的研究[2-3]。本文就PET-CT在肿瘤疗效评价中的应用进行综述并比较两种显像剂在监测肿瘤疗效时各自的价值, 同时探讨两者在监测某种特定治疗方法的疗效时何者更具有优势。
18F-FDG和18F-FLT PET-CT在肿瘤非手术治疗早期疗效评价中的应用
18F-FDG and 18F-FLT PET-CT in evaluation of the early response of malignant tumors after different therapies
-
摘要: 早期监测肿瘤在不同治疗方法中的疗效已成为临床上亟待解决的问题。PET可从分子水平上观察细胞生物学行为, 尤其是对肿瘤的早期诊断、分期及疗效评价具有较高的特异度。18F-FDG为葡萄糖类代谢显像剂, 作为目前应用最为广泛的显像剂, 因其本身固有的一些特点表现为对肿瘤的非特异性显像。3′-脱氧-3′-18F-氟胸腺嘧啶(18F-FLT)为核苷酸类代谢显像剂, 在细胞增殖显像方面的应用较为广泛。两者在肿瘤监测、分期及疗效评价方面各具特点。该文就PET-CT在肿瘤疗效评价中的应用进行综述, 同时探讨两者在监测非手术治疗疗效时何者更具有优势。
-
关键词:
- 肿瘤 /
- 氟脱氧葡萄糖F18 /
- 氟胸腺嘧啶F18 /
- 正电子发射断层显像术 /
- 疗效
Abstract: For the evaluation of the early effect of different therapies for the treatment of malignant tumors, reduction in tumor volume is the most commonly used criterion for efficacy. However, the time until tumor shrinkage can be long and it requires repeated tumor volume measurements several times weekly to show effect. Non-invasive method such as PET allows for biological processes to be visualized and quantified non-invasively over time, and it has a high specificity for the early diagnosis, staging and evaluate the response of tumors. 18F-FDG is the most widely used radiotracer for imaging in oncology and is very useful for detecting and characterizing cancers currently. But it is not a tumor specific agent for the intrinsic property. 3′-deoxy-3′-18F- fluorothymidine(18F-FLT) is used as a PET tracer for visualization of cell proliferation and it has become more widely used in clinic. Both of them have their own features in the diagnosis, staging and early detect response of tumors. This article reviewed the application of 18F-FDG and 18F-FLT to evaluate the early response of malignant tumors after different therapies. Besides, at the same time, 18F-FDG and 18F-FLT which is more specific or superiority to measure early response of tumors after definite treatment was discussed.-
Key words:
- Neoplasms /
- Fluorodeoxyglucose F18 /
- Fluorothymidine F18 /
- Positron emission tomography /
- Response
-
[1] Westerterp M, van Westreenen HL, Reitsma JB, et al. Esophageal cancer:CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy systematic review. Radiology, 2005, 236(3):841-851. [2] 章斌, 吴翼伟, 王振欣, 等. 18F-FLT PET/CT显像在鼻咽癌诊断及分期中的应用.中华核医学杂志, 2011, 31(5):306-309.
[3] Debucquoy A, Devos E, Vermaelen P, et al. 18F-FLT and 18F-FDG PET to measure response to radiotherapy combined with celecoxib in two colorectal xenograft models. Int J Radiat Biol, 2009, 85(9):763-771. [4] Wei LH, Su H, Hildebrandt IJ, et al. Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res, 2008, 14(11):3416-3426. [5] Aide N, Kinross K, Cullinane C, et al. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. J Nucl Med, 2010, 51(10):1559-1564. [6] Ullrich RT, Zander T, Neumaier B, et al. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine([F]FLT)positron emission tomography(PET). PLoS One, 2008, 3(12):e3908. [7] Uddin MK, Reignier SG, Coulter T, et al. Syntheses and antiproliferative evaluation of oxyphenisatin derivatives. Bioorg Med Chem Lett, 2007, 17(10):2854-2857. [8] Jensen MM, Erichsen KD, Björkling F, et al. Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice. PLoS One, 2010, 5(9):e12965. [9] Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature, 1965, 205(4972):698-699. [10] Leyton J, Latigo JR, Perumal M, et al.Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res, 2005, 65(10):4202-4210. [11] Guchelaar HJ, Hoekstra HJ, de Vries EG, et al. Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities. Br J Cancer, 1992, 65(6):898-902. [12] Been LB, Suurmeijer AJ, Elsinga PH, et al. 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas. J Nucl Med, 2007, 48(3):367-372. [13] van Westreenen HL, Heeren PA, Jager PL, et al. Pitfalls of positive findings in staging esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography. Ann Surg Oncol, 2003, 10(9):1100-1105. [14] Yue J, Chen L, Cabrera AR, et al. Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study. J Nucl Med, 2010, 51(4):528-534. [15] Han D, Yu J, Yu Y, et al. Comparison of 18F-fluorothymidine and 18F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus. Int J Radiat Oncol Biol Phys, 2010, 76(4):1235-1241. [16] Giammarile F, Billotey C, Lombard-Bohas C, et al. 18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumors. Nucl Med Commun, 2011, 32(2):91-97. [17] Been LB, Hoekstra HJ, Suurmeijer AJ, et al.[18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer. Oral Oncol, 2009, 45(12):e211-215. [18] Apisarnthanarax S, Alauddin MM, Mourtada F, et al. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res, 2006, 12(15):4590-4597. [19] Goldberg N, Kundel Y, Purim O, et al. Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18F-FDG PET-CT imaging. A prospective clinical study. Radiat Oncol, 2012, 7: 124. [20] Oyama N, Ponde DE, Dence C, et al. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med, 2004, 45(3):519-525. [21] Sugiyama M, Sakahara H, Sato K, et al. Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med, 2004, 45(10):1754-1758.
计量
- 文章访问数: 2093
- HTML全文浏览量: 880
- PDF下载量: 2